Search details
1.
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Ann Rheum Dis
; 83(2): 199-213, 2024 Jan 11.
Article
in English
| MEDLINE | ID: mdl-37793792
2.
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
Ann Rheum Dis
; 83(5): 547-549, 2024 Apr 11.
Article
in English
| MEDLINE | ID: mdl-38071514
3.
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase 2/3 Clinical Trials.
J Rheumatol
; 2024 Jun 01.
Article
in English
| MEDLINE | ID: mdl-38825359
4.
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.
Ann Rheum Dis
; 82(2): 212-216, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36100350
5.
ASAS consensus definition of early axial spondyloarthritis.
Ann Rheum Dis
; 2023 Jun 15.
Article
in English
| MEDLINE | ID: mdl-37321799
6.
Instrument selection for the ASAS core outcome set for axial spondyloarthritis.
Ann Rheum Dis
; 82(6): 763-772, 2023 06.
Article
in English
| MEDLINE | ID: mdl-35680390
7.
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
Ann Rheum Dis
; 82(4): 515-526, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36649967
8.
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
Ann Rheum Dis
; 82(1): 19-34, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36270658
9.
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.
Ann Rheum Dis
; 82(5): 698-709, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36787993
10.
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 2023 Nov 08.
Article
in English
| MEDLINE | ID: mdl-37947318
11.
The faecal microbiota is distinct in HLA-B27+ ankylosing spondylitis patients versus HLA-B27+ healthy controls.
Clin Exp Rheumatol
; 41(5): 1096-1104, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36441657
12.
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
Rheumatology (Oxford)
; 61(11): 4324-4334, 2022 11 02.
Article
in English
| MEDLINE | ID: mdl-35188180
13.
Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort.
Rheumatology (Oxford)
; 61(5): 2079-2087, 2022 05 05.
Article
in English
| MEDLINE | ID: mdl-34427579
14.
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
Ann Intern Med
; 174(11): 1572-1585, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34461029
15.
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Lancet
; 395(10217): 53-64, 2020 01 04.
Article
in English
| MEDLINE | ID: mdl-31813637
16.
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Ann Rheum Dis
; 80(8): 1022-1030, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33958326
17.
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis
; 80(8): 1004-1013, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33906853
18.
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis.
Ann Rheum Dis
; 80(9): 1168-1174, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34161253
19.
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
BMC Musculoskelet Disord
; 22(1): 1037, 2021 Dec 13.
Article
in English
| MEDLINE | ID: mdl-34903218
20.
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
Ann Rheum Dis
; 79(5): 595-604, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32253184